An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Inclusion Criteria

• Participant completed the Treatment Period of PD0053 (NCT04658186). The BaselineVisit for PD0055 (Visit 2) should be no later than 4 weeks following the end oftreatment (EOT) Visit in PD0053 (NCT04658186). Any delay needs to be justified bythe Investigator and approved by the Sponsor

• A male study participant must agree to use contraception during the Treatment Periodand for at least 90 days after the last dose of the IMP and refrain from donatingsperm during this period.

• A female study participant is eligible to participate if she is not pregnant, notbreastfeeding, and at least 1 of the following conditions applies:

◦ Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow thecontraceptive guidance during the Treatment Period and for at least 1 month afterthe last dose of investigational medicinal product (IMP). The study participant musthave a negative urine pregnancy test at Screening (Visit 1), which is to beconfirmed negative by urine testing prior to the first dose of IMP at PD0055Baseline Visit. If oral contraception is used, an additional barrier method will berequired during the study as an IMP-related gastrointestinal upset or a druginteraction by cytochrome P450 3A4 (CYP3A4) induction could interfere with efficacy

• Capable of giving signed informed consent which includes compliance with therequirements and restrictions listed in the Informed Consent form (ICF) and in thisprotocol.

Exclusion Criteria:

• Study participant has any medical or psychiatric condition that, in the opinion ofthe Investigator, could jeopardize or would compromise the study participant'sability to participate in this study

• A female study participant who tests positive for pregnancy, plans to get pregnantduring the participation in the study, or who is breastfeeding

• Study participant had previously participated in PD0055

• Study participant meets any withdrawal criteria in PD0053 (NCT04658186)

• Study participants wearing any kind of implantable active device, including cardiacpacemakers, pumps, and implantable cardioverters, will be excluded from usingDigital Health Technology, but may participate in the main study

• Study participant does not agree to refrain from donating blood or blood products orother body fluids